Clinical trials: Staphylococcus Aureus Infection
Staphylococcus Aureus Infection
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
This is an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus…
- Trial name
- NCT02820883
- Testing
- Staphylococcus aureus vaccine (60µg/per protein), Staphylococcus aureus vaccine (30µg/per protein), Staphylococcus aureus vaccine (15µg/per protein)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ventilator Associated Pneumonia, Staphylococcus Aureus
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE-2 (NCT05331885)
- Testing
- Suvratoxumab
- Where
- 27 sites in Belgium, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Aridis Pharmaceuticals, Inc.
Cystic Fibrosis
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
- Trial name
- STAR-TER (NCT03489629)
- Testing
- Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of North Carolina, Chapel Hill
Staphylococcus Aureus
Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making
The study EPICS-6 consists of three study phases. Emergency Department patients are screened for nasal and pharyngeal colonisation with Methicillin sensitive and Methicillin resistant Staphylococcus aureus (MSSA/MRSA) using a…
- Trial name
- EPICS-6 (NCT03220386)
- Testing
- Decolonization by nasal Octinidin treatment and skin washings
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Charite University, Berlin, Germany
Staphylococcal Skin Infections
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults
- Trial name
- NCT00463801
- Testing
- Daptomycin
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Novartis
Staphylococcus Aureus Infection
Nasal Decolonization of Dialysis Patients Noses
Hemodialysis patients are at high-risk for infections, specifically Staphylococcus aureus infections. The investigators propose to 1) implement a novel intervention (nasal povidone-iodine at each hemodialysis session) to prevent…
- Trial name
- PAINTS (NCT04210505)
- Testing
- Povidone-Iodine Topical Ointment, Standard Care
- Where
- 5 sites in United States
- Volunteers
- 302 people
- Sponsor
- Marin L. Schweizer, PhD
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.
- Trial name
- NCT02963129
- Testing
- Mupirocin
- Where
- 2 sites in Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Staphylococcal Infections
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients' Clinical Outcome in Orthopedic Device Related Bone Infections
This was a prospective study performed between November 2011 and September 2013. Patients with a confirmed S. aureus infection after fracture fixation or prosthetic joint infection were included.
- Trial name
- StaphType (NCT02971657)
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BG Unfallklinik Murnau
Infective Endocarditis, Infection Staphylococcal
NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis
Infective endocarditis is a deadly disease with a mortality rate between 20 and 40%. Antibiotic therapy is of utmost importance. It is primarily guided by microbial results from positive blood culture.
- Trial name
- NESSIE (NCT04257292)
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Jena University Hospital
Staphylococcal Infection, Abscess
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
- Conditions
- Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
- Trial name
- NCT00352612
- Testing
- clindamycin, cephalexin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aaron Chen
Staphylococcal Aureus Infection, Staphylococcus Aureus Bacteraemia
Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia
Staphylococcus aureus bacteraemia (SAB) is a major global cause of sepsis-related mortality. Randomised trials of adjunctive antibiotics, including fosfomycin, have not shown consistent benefit, possibly due to inclusion of…
- Trial name
- NCT07155590
- Where
- 2 sites in Spain
- Volunteers
- 369 people
- Sponsor
- Hospital Universitari de Bellvitge
Staphylococcus (S.) Aureus Infection
Staphylococcus Aureus Caught in Action at the Site of Infection
This study is to obtain a comprehensive view of S. aureus adaptations in the infected human host and (i) to improve the understanding of the interface between antibiotic therapy, resistance development and virulence factor…
- Trial name
- PROSA (NCT04781569)
- Testing
- data collection, blood draw, nose swabs
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Staphylococcus Aureus
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
The Swap Out Trial is a cluster randomized controlled trial of HCA hospitals, evaluating the non-inferiority of two decolonization regimens: Arm 1 Routine Care: ICU nasal decolonization with mupirocin twice daily for 5 days in…
- Trial name
- NCT03140423
- Testing
- Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization
- Where
- 137 sites in United States
- Volunteers
- 353,323 people
- Sponsor
- Harvard Pilgrim Health Care
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection…
- Trial name
- COMBAT-SAB (NCT07376889)
- Testing
- Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- Where
- 13 sites in United States
- Volunteers
- 2,096 people
- Sponsor
- Intermountain Health Care, Inc.
Staphylococcal Infection
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU.
- Trial name
- NCT01827358
- Testing
- Mupirocin calcium
- Where
- 6 sites in United States
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
The purpose of this study is to determine whether or not mupirocin treatment results in S. aureus decolonization in affected NICU patients.
- Trial name
- NCT02967432
- Testing
- Mupirocin Topical Ointment, Petroleum Jelly
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Crouse Hospital
Skin Diseases, Infectious, Skin Diseases, Bacterial
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
- Conditions
- Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
- Trial name
- NCT00210899
- Testing
- ceftobiprole medocaril, Vancomycin plus Ceftazidime
- Volunteers
- 828 people
- Sponsor
- Basilea Pharmaceutica
Staph Aureus Colonization, Staph Aureus Infection
Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial
This trial will test the hypothesis that treating parents of neonates requiring NICU care with intranasal mupirocin and topical chlorhexidine bathing will reduce the spread of S. aureus from parents to neonates.
- Trial name
- TREAT PARENTS (NCT02223520)
- Testing
- Mupirocin and Chlorhexidine
- Where
- 2 sites in United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc